国产创新药成果集中亮相国际舞台，港股创新药ETF（159567）成交额快速突破7000万元，君实生物涨超2%

Group 1 - The core viewpoint of the articles highlights the significant presence of Chinese innovative drugs on the international stage, with a record number of original research results presented at the 2025 ASCO annual meeting [1][2] - The Hong Kong stock market saw active trading in the pharmaceutical and biotechnology sector, with the Hong Kong Innovative Drug ETF (159567) experiencing a high opening but a subsequent decline of 0.77% [1] - Notable performance among component stocks included Junshi Biosciences rising over 2%, while major stocks like Innovent Biologics and WuXi Biologics faced declines [1] Group 2 - Citic Securities indicated that the concentration of innovative drug results signifies that Chinese pharmaceutical companies are rapidly advancing in international innovative research and development [2] - Some innovative drugs are targeting previously underserved indications, while others are challenging current standard treatment protocols (SOC) to reach broader markets [2] - The innovative drug industry is maintained at a rating of outperforming the broader market [2]